Boston Scientific (NYSE:BSX) announced today that it received FDA approval for its TheraSphere Y-90 glass microspheres.
Marlborough, Mass.-based Boston Scientific’s TheraSphere Y-90 glass microspheres were developed to treat those with hepatocellular carcinoma (HCC), according to a news release.
Approval for the technology offers further access to the therapy that, until now, has been utilized under a humanitarian device exemption. Boston Scientific said it is now the only radioembolization technology indicated for the treatment of unresectable HCC in the U.S.
TheraSphere provides a type of selective internal radiation therapy (SIRT) with low toxicity, comprised of millions of microscopic glass beads containing radioactive yttrium (Y-90). The glass beads are delivered directly to liver tumors via a catheter to ensure there is minimal exposure to surrounding healthy tissue.
The Legacy study of 162 participants tha…